D-0379-2026 Class II Ongoing
FDA drug recall D-0379-2026 was initiated by Harbin Jixianglong Biotech Co., Ltd. on Feb 13, 2026 and is designated Class II. Reason for recall: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 11, 2026
- Initiation Date
- Feb 13, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China
Reason for recall
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Distribution pattern
Nationwide within the United States
Code information
Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0379-2026
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026